Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus–Monoinfected Patients
- 18 March 2014
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 160 (6), 369-379
- https://doi.org/10.7326/M13-1829
Abstract
The incidence and determinants of hepatic decompensation have been incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in the antiretroviral therapy (ART) era, and few studies have compared outcome rates with those of patients with chronic HCV alone. To compare the incidence of hepatic decompensation between antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients and to evaluate factors associated with decompensation among co-infected patients receiving ART. Retrospective cohort study. Veterans Health Administration. 4280 co-infected patients who initiated ART and 6079 HCV-monoinfected patients receiving care between 1997 and 2010. All patients had detectable HCV RNA and were HCV treatment–naive. Incident hepatic decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage. The incidence of hepatic decompensation was greater among co-infected than monoinfected patients (7.4% vs. 4.8% at 10 years; P < 0.001). Compared with HCV-monoinfected patients, co-infected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competing risks, 1.56 [95% CI, 1.31 to 1.86]). Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44 [CI, 1.05 to 1.99]). Baseline advanced hepatic fibrosis (FIB-4 score >3.25) (HR, 5.45 [CI, 3.79 to 7.84]), baseline hemoglobin level less than 100 g/L (HR, 2.24 [CI, 1.20 to 4.20]), diabetes mellitus (HR, 1.88 [CI, 1.38 to 2.56]), and nonblack race (HR, 2.12 [CI, 1.65 to 2.72]) were each associated with higher rates of decompensation among co-infected patients. Observational study of predominantly male patients. Despite receiving ART, patients co-infected with HIV and HCV had higher rates of hepatic decompensation than HCV-monoinfected patients. Rates of decompensation were higher for co-infected patients with advanced liver fibrosis, severe anemia, diabetes, and nonblack race. National Institutes of Health.This publication has 62 references indexed in Scilit:
- Does an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV?Clinical Infectious Diseases, 2012
- The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis CCirculation: Cardiovascular Quality and Outcomes, 2011
- Validity of diagnostic codes and liver‐related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort StudyPharmacoepidemiology and Drug Safety, 2011
- Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NYJournal of Urban Health, 2011
- Copy-Years Viremia as a Measure of Cumulative Human Immunodeficiency Virus Viral BurdenAmerican Journal of Epidemiology, 2009
- Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosisJournal of Hepatology, 2009
- Factors Associated with Prevalent Hepatitis C Infection Among HIV-Infected Women with No Reported History of Injection Drug Use: The Women's Interagency HIV Study (WIHS)AIDS Patient Care and STDs, 2009
- Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not menAIDS, 2009
- HIV infection and the risk of diabetes mellitusAIDS, 2009
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionJournal of Hepatology, 2006